A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
NCT ID: NCT01591512
Last Updated: 2015-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
4 participants
OBSERVATIONAL
2011-05-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
NCT00222404
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
NCT00544674
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
NCT02193152
Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer
NCT05790460
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
NCT00161278
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of SCLC or mixed SCLC/non-SCLC per histopathology results
* Scheduled to undergo first-, second- or third-line treatment for SCLC, including chemotherapy, chemotherapy + radiation therapy, or combined concurrent chemoradiotherapy.
* Able to understand and willing to provide Informed Consent
Exclusion Criteria
* Not scheduled to undergo treatment for the diagnosis of SCLC
* Unable to provide Informed Consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Research Networx LLC
UNKNOWN
Fujirebio Diagnostics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kelly Family Medical Center, PC
Eastpointe, Michigan, United States
St.Louis Cancer Care, LLP
Bridgeton, Missouri, United States
Heartland Regional Medical Center
Saint Joseph, Missouri, United States
Hematology Oncology Consultants, Inc.
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDI-36
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.